PHARMAC not funding some treatments for rare, life-threatening diseases: Bosentan as an example

New Zealand Medical Journal

Volumn 118, Issue 1226, 2005, Pages

  Whyte, Ken F ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

ARTICLE; CLINICAL TRIAL; COST OF ILLNESS; DECISION MAKING; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; FATALITY; FETOTOXICITY; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HUMAN; NEW ZEALAND; PULMONARY HYPERTENSION; SYMPTOMATOLOGY; TOXIC HEPATITIS; DRUG APPROVAL; ECONOMICS; HEALTH CARE POLICY; PUBLIC HEALTH;

ANTIHYPERTENSIVE AGENTS; DRUG APPROVAL; HEALTH POLICY; HUMANS; HYPERTENSION, PULMONARY; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; SULFONAMIDES;

EID: 28844466334     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Channick RN, Simmoneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-23.
2. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
3. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. A 1 year follow up study. Chest. 2003;124:247-54.
4. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-9.
5. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-9.
6. Galie N, Rubin LJ. Pulmonary Arterial Hypertension: Epidemiology, Pathobiology, Assessment and Therapy. J Am Coll Cardiol. 2004;43 (Supplement):12.
7. Barst RJ, Rubin LJ, Long WA, et al. A comparision of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
8. Olschewski H, Simmonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-9.
9. Sastry BKD, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomised placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149-53.
10. Personal communication: HEC Panel, PHARMAC; 2005.
11. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: A preliminary decision analysis. Chest. 2003;124:2087-92.
12. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: American College of Chest Physicians Evidence-based clinical practice Guidelines. Chest 2004; 126:35S-62S.
13. Task Force on diagnosis and treatment of PAH of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J. 2004;25:2243-78.
14. Galie N, Ghofrani HA, Trobicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. Abstract available online. URL: http://content.nejm.org/cgi/content/abstract/353/20/2148 Accessed November 2005.